BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Nephera Ltd. Raises $2.85 Million


8/11/2010 7:48:12 AM

MISGAV, Israel--(BUSINESS WIRE)--Nephera, a medical device company that was started in the Misgav Venture Accelerator, today completed its second round of capitalization, in which it raised $2.85 million. Aurum Ventures, Evergreen Venture Partners, and the Trendlines Group (through its Misgav Venture Accelerator unit) took part in this round.

The investment will enable Nephera to launch clinical trials of its device for the treatment of patients suffering from congestive heart failure (CHF). The device, designed to improve and maintain kidney function during these patients’ frequent hospitalizations, is based on electrical stimulation of the urinary system. At present, the decline in kidney function during hospitalization causes a deterioration in the patient’s overall condition. The company successfully completed a round of pre-clinical trials recently and is expected to begin clinical trials in the coming months.

Nephera CEO Gill Bar-Yoseph said: “We are encouraged by the success of the investment round and thank the investors for their confidence in the company and in its product. Nephera’s solution for CHF patients is a breakthrough, especially as the prevalence of the illness has been increasing over the years. We intend to start clinical trials as soon as possible.”

According to Dr. Ronit Bendori of Evergreen Venture Partners, “The solution proposed by Nephera is unique in its simplicity and in its ability to treat a heart problem via a peripheral system, namely, the urinary system. The product developed by the company has a growing target population of CHF patients and can lead to a dramatic change in this area."

“Having witnessed the success of the pre-clinical trials,” said Dr. Dan Gelvan of Aurum Ventures, ”we believe that, together with the company’s management, we will succeed in obtaining good results in clinical trials and soon reach the stage of sales."

CHF is a major problem in industrialized countries. In the United States alone, more than a million people are hospitalized each year due to CHF; in fact, it is the leading cause of hospitalization among older patients in the US. The prevalence of the disease has increased over the years, partly due to improved medical care and the consequent rise in life expectancy.

ABOUT NEPHERA

Nephera was established in the Misgav Venture Accelerator in 2008. It is developing a device to treat patients suffering from congestive heart failure based on electrical stimulation of the urinary system. The company recently completed a round of pre-clinical trials and is expected to begin clinical trials in the near future.

ABOUT MISGAV

The Misgav Venture Accelerator (http://www.misgav-venture.com), founded in 1992, specializes in medical instrumentation, pharmaceutical, and biotechnology companies. Recently, it was named “Best Incubator” of 2009 by the Chief Scientist. The Israeli Trendlines Group owns a controlling interest in the accelerator.

ABOUT AURUM VENTURES

Aurum Ventures MKI is the technology investment arm of Morris Kahn, a prominent businessman, philanthropist, and entrepreneur. Aurum invests in life-sciences and cleantech companies based in or connected to Israel, in all stages of development.

ABOUT EVERGREEN

Evergreen Venture Partners, founded in 1987, has become a leader in the Israeli venture capital market. It invests in startups specializing in software, the Internet and new media, communications, and the life sciences, remaining with them throughout their lives starting with the initial stages. Evergreen manages $700 million in venture capital funds and has so far invested in more than 120 startups. Evergreen has had 37 successful exits involving stock issues or the sale of companies, including Exalink, BigBand, Traiana, Colbar, Identify, and Dune. For further information, please visit the company’s website: www.evergreen.co.il.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES